Virax Biolabs Group Limited
VRAXHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeVirax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and. The company carries a $1.6M market cap, placing it firmly in the micro-cap category. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease.
Market Cap
$1.6M
Beta
1.39
P/E (TTM)
—
P/E (Fwd)
-0.20
EPS (TTM)
$-12.49
EPS (Fwd)
$-6.00
ROE
-78.6%
ROA
-54.2%
Cash
$6.5M
Total Debt
$414,387
Free CF
-$3.5M
52W Change
-91.7%
Annual Financials
Cash vs Debt
Where VRAX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, VRAX finished 60.34% below its 150-day moving average ($3.53) and 67.21% below its 200-day moving average ($4.27). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VRAX overbought or oversold?
At the October 20, 2026 close, VRAX's RSI(14) was 22.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Virax Biolabs Group Limited holds $6.5M in cash against $414K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$3.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -78.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $9K (2023) to $12K (2026), reflecting a 45% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VRAX.